Peel Therapeutics a US-based clinical-stage biotech company developing medicines for cancer and inflammatory diseases, announced on Wednesday that it has started a first-in-human clinical study of PEEL-224 in patients with advanced solid tumours.
This move is subsequent to the recent acceptance of the company's Investigational New Drug (IND) Application by the United States Food and Drug Administration (FDA).
The product was produced from a medicine that originates from the leaves and stem of an ancient tree used for thousands of years in traditional Chinese medicine.
The firm is assessing the product in a Phase one dose escalation, repeat-dose, multi-centre, open-label study in patients with advanced solid tumours. The trial is to assess PEEL-224's safety, tolerability, pharmacokinetics and preliminary antitumor activity.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval